Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Instagram Outage Disrupts Thousands of U.S. Users 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
 - EconoTimes)
RALEIGH, N.C., March 31, 2016 -- PRA Health Sciences (PRA) (NASDAQ:PRAH), is pleased to announce that it received a “Highly Commended” designation by Vaccine Industry Excellence (ViE) for Best Contract Research Organization. PRA was originally named a finalist in the category based on industry nominations. Finalists submitted a detailed questionnaire about their vaccine capabilities which was then blinded, reviewed, and rated by a panel of judges.
“This is a great honor,” said Frank Hijek, PRA Senior Vice President, Strategic Drug Development. “By combining PRA’s therapeutic expertise and experience with proven strategies and innovative approaches, we are redefining vaccine clinical research. This recognition speaks to our commitment to accelerate vaccine development.”
PRA’s vaccine experience includes Phase I - Phase IV adult and pediatric studies involving nearly 213,000 study participants at more than 3,000 sites around the world. In the past five years, PRA teams have participated in over 140 vaccine studies; these include studies that led to the approval of six vaccines that are currently on the market. More information about PRA’s Vaccine Solutions group can be found at www.pravaccinesolutions.com.
ABOUT PRA HEALTH SCIENCES
PRA is one of the world's leading global contract research organizations, by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. PRA’s global clinical development platform includes approximately 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East, and approximately 12,000 employees worldwide. Since 2000, PRA has performed approximately 3,300 clinical trials worldwide and has worked on more than 100 marketed drugs across several therapeutic areas. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 60 drugs. To learn more about PRA, please visit www.prahs.com.
INQUIRIES: Christine Rogers, Manager - Public Relations, Corporate Communications EMAIL: [email protected] PHONE: +1 919.786.8463
